Myeloproliferative Neoplasms

Test Your Knowledge

Quiz: Which Mutation Was Identified as High-Risk Bleeding Factor in MPN?

11/11/2021

Which of the following mutations was identified as a high-risk bleeding factor in MPN?

Which of the following mutations...

11/11/2021

Oncology

Podcasts

Pacritinib Promising for Patients With Myelofibrosis and Severe Thrombocytopenia

01/21/2020

John Mascarenhas, MD, discusses a retrospective analysis of 2 clinical trials evaluating pacritnib for myelofibrosis and severe thrombocytopenia.

John Mascarenhas, MD, discusses...

01/21/2020

Oncology

News

Luspatercept Demonstrates Long-Term Safety and Efficacy for Anemia in Patients With MDS

12/27/2019

Long-term analyses of the MEDALIST study show sustained responses with durable clinical benefit in patients with MDS receiving luspatercept for anemia, superior to that of patients receiving placebo.

Long-term analyses of the...

12/27/2019

Oncology

News

Luspatercept Active in Patients with Myelofibrosis-Associated Anemia

12/27/2019

Initial results from an ongoing study suggest clinically significant activity of luspatercept for the treatment of myelofibrosis-associated anemia.

Initial results from an ongoing...

12/27/2019

Oncology

News

Ruxolitinib Plus Pomalidomide Feasible for Treatment of MF With Anemia

12/18/2019

Combining ruxolitinib therapy with pomalidomide is feasible for the treatment of patients with poor-risk MF and anemia, updated study findings show.

Combining ruxolitinib therapy...

12/18/2019

Oncology

Videos

Navitoclax Plus Ruxolitinib Yields Encouraging Responses in Myelofibrosis

12/16/2019

Jacqueline Garcia, MD, discusses results from a phase 2 study of navitoclax in combination with ruxolitinib for patients with primary or secondary myelofibrosis.

Jacqueline Garcia, MD, discusses...

12/16/2019

Oncology

Videos

Indications for Transplant in Low/Intermediate Risk MDS

11/07/2019

Koen van Besien, MD, PhD, discusses data on the indications for transplant for patients with low and intermediate‑grade MDS.

Koen van Besien, MD, PhD,...

11/07/2019

Oncology

Videos

Michael R. Savona, MD, Discusses Diagnosis and Treatment Options for CMML

06/27/2019

Michael R. Savona, MD, explains some of the challenges with diagnosing chronic myelomonocytic leukemia (CMML) and treatment options that are currently available and being studied for these patients.

Michael R. Savona, MD, explains...

06/27/2019

Oncology

Ruxolitinib Improves Therapy Response With Less Toxicity in Early Primary MF

12/11/2018

Patients with early primary myelofibrosis are likely to have better responses and lower toxicities from ruxolitinib treatment, according to a recent study presented at ASH 2018.

Patients with early primary...

12/11/2018

Oncology

Incorporation of Immune Checkpoint Inhibitors Promising for MDS

12/05/2018

Immune checkpoint inhibitors demonstrate significant activity in myelodysplastic syndrome with an acceptable toxicity profile, according to a recent study presented at ASH 2018.

Immune checkpoint inhibitors...

12/05/2018

Oncology